Immuron Crescita futura

Future criteri di controllo 2/6

Si prevede che Immuron aumenterà i profitti e i ricavi rispettivamente del 22.4% e 59.7% all'anno.

Informazioni chiave

22.4%

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Biotechs crescita degli utili	15.3%
Tasso di crescita dei ricavi	59.7%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	26 Sep 2024

Aggiornamenti recenti sulla crescita futura

Nessun aggiornamento

Recent updates

Previsioni di crescita degli utili e dei ricavi

ASX:IMC - Stime future degli analisti e dati finanziari passati (AUD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2026	15	-4	N/A	N/A	1
6/30/2025	6	-8	N/A	N/A	1
6/30/2024	5	-7	-6	-6	N/A
3/31/2024	4	-5	-5	-5	N/A
12/31/2023	4	-4	-4	-4	N/A
9/30/2023	3	-4	-3	-3	N/A
6/30/2023	2	-4	-3	-3	N/A
3/31/2023	1	-3	-2	-2	N/A
12/31/2022	1	-3	-2	-2	N/A
9/30/2022	1	-3	-2	-2	N/A
6/30/2022	1	-3	-3	-3	N/A
3/31/2022	1	-4	-3	-3	N/A
12/31/2021	0	-4	-4	-4	N/A
9/30/2021	0	-6	-4	-4	N/A
6/30/2021	0	-8	-4	-4	N/A
3/31/2021	1	-8	N/A	N/A	N/A
12/31/2020	1	-7	-4	-4	N/A
9/30/2020	2	-5	-4	-4	N/A
6/30/2020	3	-3	-3	-3	N/A
3/31/2020	3	-4	N/A	N/A	N/A
12/31/2019	3	-5	-3	-3	N/A
9/30/2019	3	-5	-2	-2	N/A
6/30/2019	2	-5	-2	-2	N/A
3/31/2019	2	-4	-1	-1	N/A
12/31/2018	2	-3	-1	-1	N/A
9/30/2018	2	-3	-2	-2	N/A
6/30/2018	2	-3	-4	-4	N/A
3/31/2018	2	-4	N/A	-6	N/A
12/31/2017	2	-5	N/A	-8	N/A
9/30/2017	2	-6	N/A	-8	N/A
6/30/2017	1	-7	N/A	-7	N/A
3/31/2017	1	-8	N/A	-5	N/A
12/31/2016	1	-6	N/A	-4	N/A
9/30/2016	1	-6	N/A	-5	N/A
6/30/2016	1	-7	N/A	-5	N/A
3/31/2016	1	-5	N/A	-5	N/A
12/31/2015	1	-4	N/A	-5	N/A
9/30/2015	1	-4	N/A	-4	N/A
6/30/2015	1	-3	N/A	-3	N/A
3/31/2015	1	-3	N/A	-3	N/A
12/31/2014	1	-2	N/A	-3	N/A
9/30/2014	1	-2	N/A	-3	N/A
6/30/2014	1	-2	N/A	-3	N/A
3/31/2014	1	-3	N/A	-2	N/A
12/31/2013	0	-3	N/A	-2	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che IMC rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che IMC rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che IMC rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di IMC ( 59.7% all'anno) crescerà più rapidamente del mercato Australian ( 5.7% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di IMC ( 59.7% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di IMC è previsto essere elevato tra 3 anni

Immuron Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Recent updates

Immuron Limited, Annual General Meeting, Nov 18, 2024

Immuron Limited Announces NMRC Reports Results for Campylobacter Clinical Study

Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)

Full year 2024 earnings released: AU$0.03 loss per share (vs AU$0.017 loss in FY 2023)

Immuron Limited has filed a Follow-on Equity Offering in the amount of $2.069083 million.

Immuron Requests Pre-IND Meeting for IMM-529 with FDA Filing

Immuron Limited Appoints Jeannette Joughin as Director

Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director

We're Not Very Worried About Immuron's (ASX:IMC) Cash Burn Rate

Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US

Immuron Limited Clinical Trials Update

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Immuron Limited, Annual General Meeting, Nov 21, 2023

Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.013 loss in FY 2022)

Immuron Limited Announces First Patients Enrolled in Travelan® Clinical Study

Immuron Limited Initiates Recruitment of Travelan Clinical Study

Immuron Limited Announces US Food and Drug Administration Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves Way for Clinical Trial Initiation

First half 2023 earnings released: AU$0.009 loss per share (vs AU$0.008 loss in 1H 2022)

Immuron US DoD Naval Medical Research Center Responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic

Immuron Limited Receives FDA Approval for Travelan IND Application

Immuron Limited Submits IND Application To FDA for Travelan

Insufficient new directors

Immuron Limited, Annual General Meeting, Oct 28, 2022

Full year 2022 earnings released: AU$0.013 loss per share (vs AU$0.038 loss in FY 2021)

Immuron Limited Provides Update on IMM-124E SARS-CoV-2 Research

Immuron Limited Provides Update on IND Application for Campylobacter ETEC Therapeutic

Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic

Immuron Limited Provides Update on the Planned Clinical Trial to Evaluate the Efficacy of Travelan and Two Third Party Non-Antibiotic Products in Travelers' Diarrhea

Immuron Limited Appoints Steven Lydeamore as Chief Executive Officer, effective June 27, 2022

Insufficient new directors

Immuron Limited Announces Work on the Investigational New Drug Application to Evaluate the Efficacy of A Single Dose Regimen of Travelan

First half 2022 earnings: Revenues and EPS in line with analyst expectations

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

Full year 2021 earnings released: AU$0.038 loss per share (vs AU$0.017 loss in FY 2020)

Executive Vice Chairman Peter Anastasiou has left the company

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

Insufficient new directors

Immuron Limited Provides Monash University Research Update on SARS-CoV-2 Program

We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth

First half 2021 earnings released: AU$0.026 loss per share (vs AU$0.009 loss in 1H 2020)

Have Insiders Been Selling Immuron Limited (ASX:IMC) Shares This Year?

New 90-day low: AU$0.21

New 90-day low: AU$0.21

Immuron Limited Provides Update on Progress of the Anti-Viral Activity of IMM-124E

Immuron Limited Announces That the Naval Medical Research Center Has Completed the Characterisation of the Colostrum Harvested from Cows Immunized with the Experimental Vaccine Developed to Target Campylobacter and Enterotoxigenic E.Coli

Immuron Limited Announces US DoD NMRC Reports Positive Response to Vaccine

New 90-day low: AU$0.23

Immuron Limited Provides Shareholders and the Market with an Update on the Planned Clinical Programs in Travelers’ Diarrhea

Full year earnings released - AU$0.017 loss per share

Immuron Limited has completed a Follow-on Equity Offering in the amount of $20.000025 million.

New 90-day high - AU$0.85

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita